evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 14.3%High 6 · 85.7%

Benralizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Rate of exacerbations requiring emergency department treatment or admission · people with asthma

Benralizumab subcutaneous (SC) probably leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review